Evidence map›Paper›PMID 18950503›Full record

ArticleBMC molecular biology2008

Novel RNA-binding properties of the MTG chromatin regulatory proteins.

Stefano Rossetti, Leontine van Unen, Nicoletta Sacchi, Andre T Hoogeveen

Open access · hybridAbstract read
In one paragraph

Article in BMC molecular biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Stefano RossettiCancer Genetics Program, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. stefano.rossetti@roswellpark.org
Leontine van Unen
Nicoletta Sacchi
Andre T Hoogeveen
Cancer Genetics (United States) · USErasmus MC · NLErasmus University Rotterdam · NLRoswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
NCI NIH HHS CA016056NCI NIH HHS P30 CA016056
6 · The paper itself

Abstract

backgroundThe myeloid translocation gene (MTG) proteins are non-DNA-binding transcriptional regulators capable of interacting with chromatin modifying proteins. As a consequence of leukemia-associated chromosomal translocations, two of the MTG proteins, MTG8 and MTG16, are fused to the DNA-binding domain of AML1, a transcriptional activator crucial for hematopoiesis. The AML1-MTG fusion proteins, as the wild type MTGs, display four conserved homology regions (NHR1-4) related to the Drosophila nervy protein. Structural protein analyses led us to test the hypothesis that specific MTG domains may mediate RNA binding.

resultsBy using an RNA-binding assay based on synthetic RNA homopolymers and a panel of MTG deletion mutants, here we show that all the MTG proteins can bind RNA. The RNA-binding properties can be traced to two regions: the Zinc finger domains in the NHR4, which mediate Zinc-dependent RNA binding, and a novel short basic region (SBR) upstream of the NHR2, which mediates Zinc-independent RNA binding. The two AML1-MTG fusion proteins, retaining both the Zinc fingers domains and the SBR, also display RNA-binding properties.

conclusionEvidence has been accumulating that RNA plays a role in transcriptional control. Both wild type MTGs and chimeric AML1-MTG proteins display in vitro RNA-binding properties, thus opening new perspectives on the possible involvement of an RNA component in MTG-mediated chromatin regulation.

Indexed as

ChromatinCore Binding Factor Alpha 2 SubunitDNA-Binding ProteinsHumansMutant Chimeric ProteinsPhosphoproteinsProto-Oncogene ProteinsRepressor ProteinsRNARNA-Binding ProteinsRUNX1 Translocation Partner 1 ProteinTranscription FactorsTranscription, GeneticTumor Suppressor ProteinsCBFA2T3 protein, humanChromatinCore Binding Factor Alpha 2 SubunitDNA-Binding ProteinsMutant Chimeric ProteinsPhosphoproteinsProto-Oncogene ProteinsRepressor ProteinsRNARNA-Binding ProteinsRUNX1 protein, humanRUNX1T1 protein, humanRUNX1 Translocation Partner 1 ProteinTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID18950503
PMCPMC2579434
OpenAlexW2170102510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.